Thoracic aorta graft infection by avibactam-resistant KPC-producing K. pneumoniae treated with meropenem/vaborbactam: a case report and literature review.

Abstract

Meropenem/vaborbactam (M/V) is a new carbapenem-carbapenemase inhibitor combination drug active against extensively drug resistant Gram-negative pathogens. Studies about its efficacy and place in therapy are limited in "real-life" and no data are available for deep site infections, like vascular graft infections. We present a case of a patient successfully treated with M/V for a thoracic aorta graft infection, placed for a traumatic penetrating aortic ulcer, due to an extensively KPC-producing Klebsiella pneumoniae resistant to ceftazidime/ avibactam. Furthermore, we conducted a systematic literature review concerning vascular graft infections caused by carbapenem-resistant Klebsiella pneumoniae and the papers published until now about the use of M/V for the treatment of ceftazidime/avibactam-resistant K. pneumoniae. Meropenem/vaborbactam is a promising antibiotic for difficult-to-treat Gram-negative bacteria with limited therapeutic options. Only few reports have been published and more studies are needed to assess which is the best place in therapy of M/V.

• Authors: Alessandra Belati, Roberta Novara, Davide Fiore Bavaro, Andrea Procopio, Cecilia Fico, Lucia Diella, Federica Romanelli, Stefania Stolfa, Adriana Mosca, Francesco Di Gennaro, Annalisa Saracino
• Journal: Le infezioni in medicina (Infez Med) Vol. 30 Issue 2 Pg. 277-284 ( 2022) ISSN: 2532-8689 [Electronic] Italy
• PMID: 35693053 (Publication Type: Case Reports)
• Copyright: Copyright © 2016 - 2022 InfezMed.